DK3389717T3 - Neoadjuvansterapi for blærekræft - Google Patents
Neoadjuvansterapi for blærekræft Download PDFInfo
- Publication number
- DK3389717T3 DK3389717T3 DK16819894.3T DK16819894T DK3389717T3 DK 3389717 T3 DK3389717 T3 DK 3389717T3 DK 16819894 T DK16819894 T DK 16819894T DK 3389717 T3 DK3389717 T3 DK 3389717T3
- Authority
- DK
- Denmark
- Prior art keywords
- bladder cancer
- neoadjuvant therapy
- neoadjuvant
- therapy
- bladder
- Prior art date
Links
- 206010005003 Bladder cancer Diseases 0.000 title 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title 1
- 238000009099 neoadjuvant therapy Methods 0.000 title 1
- 201000005112 urinary bladder cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/061—Bladder and/or urethra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0626—Monitoring, verifying, controlling systems and methods
- A61N2005/0629—Sequential activation of light sources
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
- A61N2005/0663—Coloured light
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1522309.2A GB201522309D0 (en) | 2015-12-17 | 2015-12-17 | Use |
| PCT/EP2016/081803 WO2017103283A1 (en) | 2015-12-17 | 2016-12-19 | Neoadjuvant therapy for bladder cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3389717T3 true DK3389717T3 (da) | 2025-03-31 |
Family
ID=55311159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16819894.3T DK3389717T3 (da) | 2015-12-17 | 2016-12-19 | Neoadjuvansterapi for blærekræft |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10556010B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3389717B9 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6926086B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102787188B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN119345359A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016372573B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018012009B1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3389717T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3015668T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3389717T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201522309D0 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3389717T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017103283A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522311D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| GB201522309D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| RU2760132C1 (ru) * | 2017-12-01 | 2021-11-22 | ЭсБиАй ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Фармацевтическая композиция для усиления противоопухолевого эффекта ингибитора иммунной контрольной точки |
| KR102441358B1 (ko) | 2020-09-14 | 2022-09-06 | 주식회사 아파트엔 | 아파트의 지수화를 통한 아파트 투자 가치 평가 시스템 |
| KR20250154511A (ko) | 2023-03-07 | 2025-10-28 | 포토큐어 에이에스에이 | 방광암 치료 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122006000051I2 (de) | 1995-03-10 | 2010-07-08 | Photocure Asa Hoffsveien 48 | Ester der 5-Aminolevulinsäure als Mittel zur Photosensibilisierung in der Chemotherapie |
| US7530461B2 (en) * | 1995-03-10 | 2009-05-12 | Photocure Asa | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
| GB0018528D0 (en) * | 2000-07-27 | 2000-09-13 | Photocure Asa | Compounds |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| GB0406917D0 (en) | 2004-03-26 | 2004-04-28 | Photocure Asa | Compounds |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| TWI605828B (zh) | 2008-12-09 | 2017-11-21 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| RU2526803C2 (ru) | 2009-06-11 | 2014-08-27 | ФотоКьюэр АСА | Полутвердые композиции и фармацевтические продукты |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| SG10201603055WA (en) | 2012-05-31 | 2016-05-30 | Genentech Inc | Methods Of Treating Cancer Using PD-L1 Axis Binding Antagonists And VEGF Antagonists |
| US8927761B2 (en) | 2012-06-28 | 2015-01-06 | Photocure Asa | Form of hexyl-5-aminolevulinate hydrochloride and methods of using the same |
| AU2013298525B2 (en) * | 2012-08-03 | 2017-12-14 | Photocure Asa | Compounds |
| GB201522309D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| CN109010850B (zh) * | 2018-08-01 | 2021-10-22 | 上海师范大学 | 一种负载姜黄素的葡聚糖修饰的钆掺杂的空心介孔二氧化硅纳米材料的制备方法及应用 |
-
2015
- 2015-12-17 GB GBGB1522309.2A patent/GB201522309D0/en not_active Ceased
-
2016
- 2016-12-19 KR KR1020187020006A patent/KR102787188B1/ko active Active
- 2016-12-19 AU AU2016372573A patent/AU2016372573B2/en active Active
- 2016-12-19 CN CN202411498667.9A patent/CN119345359A/zh active Pending
- 2016-12-19 JP JP2018531667A patent/JP6926086B2/ja active Active
- 2016-12-19 ES ES16819894T patent/ES3015668T3/es active Active
- 2016-12-19 PL PL16819894.3T patent/PL3389717T3/pl unknown
- 2016-12-19 BR BR112018012009-0A patent/BR112018012009B1/pt active IP Right Grant
- 2016-12-19 FI FIEP16819894.3T patent/FI3389717T3/fi active
- 2016-12-19 WO PCT/EP2016/081803 patent/WO2017103283A1/en not_active Ceased
- 2016-12-19 DK DK16819894.3T patent/DK3389717T3/da active
- 2016-12-19 EP EP16819894.3A patent/EP3389717B9/en active Active
- 2016-12-19 CN CN201680079674.2A patent/CN108601836A/zh active Pending
- 2016-12-19 US US16/063,185 patent/US10556010B2/en active Active
-
2020
- 2020-01-21 US US16/748,332 patent/US11311620B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10556010B2 (en) | 2020-02-11 |
| US20200155683A1 (en) | 2020-05-21 |
| AU2016372573B2 (en) | 2022-07-21 |
| BR112018012009A2 (pt) | 2018-12-04 |
| RU2018124868A (ru) | 2020-01-27 |
| CA3008551A1 (en) | 2017-06-22 |
| FI3389717T3 (fi) | 2025-04-08 |
| KR102787188B1 (ko) | 2025-03-25 |
| AU2016372573A1 (en) | 2018-07-12 |
| RU2018124868A3 (cg-RX-API-DMAC7.html) | 2020-05-13 |
| GB201522309D0 (en) | 2016-02-03 |
| BR112018012009B1 (pt) | 2023-12-19 |
| ES3015668T3 (en) | 2025-05-07 |
| PL3389717T3 (pl) | 2025-06-09 |
| JP2018537514A (ja) | 2018-12-20 |
| JP6926086B2 (ja) | 2021-08-25 |
| EP3389717A1 (en) | 2018-10-24 |
| US20180369379A1 (en) | 2018-12-27 |
| EP3389717B9 (en) | 2025-07-23 |
| WO2017103283A1 (en) | 2017-06-22 |
| EP3389717B1 (en) | 2025-02-19 |
| CN108601836A (zh) | 2018-09-28 |
| KR20180094987A (ko) | 2018-08-24 |
| US11311620B2 (en) | 2022-04-26 |
| CN119345359A (zh) | 2025-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3651772A4 (en) | ANTI-CANCER POLYTHERAPY | |
| IL261468A (en) | Uterine cancer treatments | |
| IL255261A0 (en) | Methods for treating cancer | |
| HUE053903T2 (hu) | Kombinációs terápia rák ellen | |
| IL255312A0 (en) | Therapeutic and diagnostic methods for cancer | |
| EP3463464A4 (en) | ASSOCIATION TREATMENT | |
| HUE054012T2 (hu) | Kombinációs terápia rák ellen | |
| HUE057061T2 (hu) | Kombinációs terápia rák kezelésére | |
| KR20180084772A (ko) | 암 치료를 위한 조합 치료법 | |
| IL284875A (en) | Lasofoxifene treatment of breast cancer | |
| PL3458052T3 (pl) | Leczenie skojarzone nowotworu | |
| EP3474854A4 (en) | DRUG ASSOCIATIONS FOR THE TREATMENT OF CANCER | |
| EP3413927A4 (en) | CANCER THERAPY | |
| IL268463A (en) | Cancer treatment | |
| DK3768830T5 (da) | Cancerterapi | |
| EP3546020C0 (en) | CANCER TREATMENT DEVICE | |
| EP3593139C0 (en) | CANCER BIOMARKERS | |
| EP3576791A4 (en) | CALRETICULIN-MEDIATION CANCER TREATMENT | |
| HUE056897T2 (hu) | Monomaleimid-funkcionalizált platinavegyületek rákterápiához | |
| HUE040167T2 (hu) | Rákkezelés | |
| DK3393478T3 (da) | Kombinationsterapi | |
| DK3383385T3 (da) | Melflufen-doseringsregimer for cancer | |
| EP3362091A4 (en) | COMBINATION THERAPY | |
| DK3389717T3 (da) | Neoadjuvansterapi for blærekræft | |
| DK3407909T5 (da) | Cancerbehandling |